Connect your AI

Precigen PGEN Cash Cash Equivalents And Short Term Investments

Cash Cash Equivalents And Short Term Investments at other companies

Viridian Therapeutics, Inc.VRDN

——

Agios PharmaceuticalsAGIO

——

Roivant SciencesROIV

——

Other financials

Income statement

Revenue$23.3M+1,634%

Operating income-$6.0M+73.5%

Net income-$7.9M+85.4%

EPS (diluted)-$0.02+88.9%

Balance sheet

Cash & equivalents$7.5M+23.5%

Total debt$98.3M+1,714%

Total equity$20.2M+244%

Total assets$138.6M+7.6%

Cash flow

Operating cash flow-$43.8M-168%

CapEx$258.0K-58.5%

Free cash flow-$44.1M-160%

Valuation

Market cap$1.93B+213%

Profitability

Gross margin83.6%—

Operating margin-2,890.9%—

Net margin-3,656%—

FCF margin-1,756.5%—

Returns & leverage

Return on equity-843.6%-1,103pp

Debt / equity4.9×—

Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsAndShortTermInvestments.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's cash cash equivalents and short term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Precigen's cash cash equivalents and short term investments?: Precigen (PGEN) reported cash cash equivalents and short term investments of $56.74M in Q1 2026.
How has Precigen's cash cash equivalents and short term investments changed year-over-year?: Precigen's cash cash equivalents and short term investments decreased by 29.9% year-over-year, from $80.99M to $56.74M.